{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T07:12:42Z","timestamp":1790233962325,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["BM1301"],"award-info":[{"award-number":["BM1301"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ANR MRFOCUS","award":["ANR-15-CE14-0032-02"],"award-info":[{"award-number":["ANR-15-CE14-0032-02"]}]},{"name":"Fight-HF Avenir investment program","award":["ANR-15-RHUS-0004"],"award-info":[{"award-number":["ANR-15-RHUS-0004"]}]}],"content-domain":{"domain":["jmmc-online.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Molecular and Cellular Cardiology"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.yjmcc.2018.06.008","type":"journal-article","created":{"date-parts":[[2018,7,5]],"date-time":"2018-07-05T22:58:22Z","timestamp":1530831502000},"page":"124-133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["Mineralocorticoid receptor antagonism improves diastolic dysfunction in chronic kidney disease in mice"],"prefix":"10.1016","volume":"121","author":[{"given":"Benjamin","family":"Bonnard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Pieronne-Deperrois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4022-7889","authenticated-orcid":false,"given":"Zoubir","family":"Djerada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumaya","family":"Elmoghrabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kolkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Ouvrard-Pascaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Mulder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Jaisser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smail","family":"Messaoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yjmcc.2018.06.008_bb0005","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1161\/CIRCULATIONAHA.114.008720","article-title":"Global and regional patterns in cardiovascular mortality from 1990 to 2013","volume":"132","author":"Roth","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.yjmcc.2018.06.008_bb0010","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrcardio.2010.165","article-title":"Epidemiology and risk profile of heart failure","volume":"8","author":"Bui","year":"2011","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.yjmcc.2018.06.008_bb0015","first-page":"329","article-title":"Management of chronic heart failure in the older population","volume":"11","author":"Azad","year":"2014","journal-title":"J. Geriatr. Cardiol. JGC"},{"key":"10.1016\/j.yjmcc.2018.06.008_bb0020","doi-asserted-by":"crossref","first-page":"629","DOI":"10.7326\/0003-4819-134-8-200104170-00007","article-title":"Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial","volume":"134","author":"Mann","year":"2001","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.yjmcc.2018.06.008_bb0025","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1161\/01.CIR.102.2.203","article-title":"Renal function, neurohormonal activation, and survival in patients with chronic heart failure","volume":"102","author":"Hillege","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.yjmcc.2018.06.008_bb0030","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jacc.2003.07.031","article-title":"Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure","volume":"43","author":"Forman","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.yjmcc.2018.06.008_bb0035","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0272-6386(03)00372-X","article-title":"Cardiovascular complications in chronic kidney disease","volume":"41","author":"Sarnak","year":"2003","journal-title":"Am. J. Kidney Dis. Off. J. Natl. Kidney Found."},{"key":"10.1016\/j.yjmcc.2018.06.008_bb0040","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.amjmed.2010.05.030","article-title":"Managing chronic heart failure patient in chronic kidney disease","volume":"124","author":"Abdo","year":"2011","journal-title":"Am. J. Med."},{"key":"10.1016\/j.yjmcc.2018.06.008_bb0045","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yjmcc.2018.06.008_bb0050","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yjmcc.2018.06.008_bb0055","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yjmcc.2018.06.008_bb0060","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1124\/pr.115.011106","article-title":"Emerging roles of the mineralocorticoid receptor in pathology: toward new paradigms in clinical pharmacology","volume":"68","author":"Jaisser","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.yjmcc.2018.06.008_bb0065","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/cmdc.201200081","article-title":"Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases","volume":"7","author":"B\u00e4rfacker","year":"2012","journal-title":"ChemMedChem"},{"key":"10.1016\/j.yjmcc.2018.06.008_bb0070","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur. Heart J."},{"issue":"12","key":"10.1016\/j.yjmcc.2018.06.008_bb0075","article-title":"Transthoracic echocardiography reference values in juvenile and adult 129\/Sv mice","volume":"11","author":"Vinhas","year":"2013","journal-title":"Cardiovasc. Ultrasound"},{"key":"10.1016\/j.yjmcc.2018.06.008_bb0080","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s10554-014-0454-4","article-title":"Non-invasive in vivo measurement of cardiac output in C57BL\/6 mice using high frequency transthoracic ultrasound: evaluation of gender and body weight effects","volume":"30","author":"Dom\u00ednguez","year":"2014","journal-title":"Int. J. Card. Imaging"},{"issue":"7","key":"10.1016\/j.yjmcc.2018.06.008_bb0085","doi-asserted-by":"crossref","DOI":"10.1186\/gb-2002-3-7-research0034","article-title":"Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes","volume":"3","author":"Vandesompele","year":"2002","journal-title":"Genome Biol."},{"key":"10.1016\/j.yjmcc.2018.06.008_bb0090","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.1172\/JCI39845","article-title":"Latent TGF-beta-binding protein 4 modifies muscular dystrophy in mice","volume":"119","author":"Heydemann","year":"2009","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.yjmcc.2018.06.008_bb0095","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.yjmcc.2018.06.008_bb0100","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1681\/ASN.2012020145","article-title":"Associations between kidney function and subclinical cardiac abnormalities in CKD","volume":"23","author":"Park","year":"2012","journal-title":"J. Am. Soc. Nephrol. JASN"},{"issue":"280","key":"10.1016\/j.yjmcc.2018.06.008_bb0105","article-title":"Diastolic function is a strong predictor of mortality in patients with chronic kidney disease","volume":"14","author":"Farshid","year":"2013","journal-title":"BMC Nephrol."},{"issue":"49","key":"10.1016\/j.yjmcc.2018.06.008_bb0110","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1161\/01.HYP.0000252409.36927.05","article-title":"Marinobufagenin stimulates fibroblast collagen production and causes fibrosis in experimental uremic cardiomyopathy","volume":"1979","author":"Elkareh","year":"2007","journal-title":"Hypertens Dallas Tex"},{"issue":"47","key":"10.1016\/j.yjmcc.2018.06.008_bb0115","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1161\/01.HYP.0000202594.82271.92","article-title":"Central role for the cardiotonic steroid marinobufagenin in the pathogenesis of experimental uremic cardiomyopathy","volume":"1979","author":"Kennedy","year":"2006","journal-title":"Hypertens Dallas Tex"},{"key":"10.1016\/j.yjmcc.2018.06.008_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0009543","article-title":"Culture-modified bone marrow cells attenuate cardiac and renal injury in a chronic kidney disease rat model via a novel Antifibrotic mechanism","volume":"5","author":"Yuen","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.yjmcc.2018.06.008_bb0125","doi-asserted-by":"crossref","first-page":"F450","DOI":"10.1152\/ajprenal.00472.2007","article-title":"Partial nephrectomy as a model for uremic cardiomyopathy in the mouse","volume":"294","author":"Kennedy","year":"2008","journal-title":"Am. J. Physiol.-Ren. Physiol."},{"key":"10.1016\/j.yjmcc.2018.06.008_bb0130","article-title":"Myocardial dysfunction occurs prior to changes in ventricular geometry in mice with chronic kidney disease (CKD)","volume":"4","author":"Winterberg","year":"2016","journal-title":"Phys. Rep."},{"key":"10.1016\/j.yjmcc.2018.06.008_bb0135","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/ki.2008.690","article-title":"Uremic cardiac hypertrophy is reversed by rapamycin but not by lowering of blood pressure","volume":"75","author":"Siedlecki","year":"2009","journal-title":"Kidney Int."},{"key":"10.1016\/j.yjmcc.2018.06.008_bb0140","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1080\/00365510802037272","article-title":"Cardiac structure and function in a mouse model of uraemia without hypertension","volume":"68","author":"Bro","year":"2008","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"10.1016\/j.yjmcc.2018.06.008_bb0145","doi-asserted-by":"crossref","first-page":"F1253","DOI":"10.1152\/ajprenal.00392.2012","article-title":"Target organ cross talk in cardiorenal syndrome: animal models","volume":"303","author":"Bongartz","year":"2012","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.yjmcc.2018.06.008_bb0150","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/MAJ.0000000000000514","article-title":"Heart failure and chronic kidney disease: should we use spironolactone?","volume":"350","author":"Agrawal","year":"2015","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.yjmcc.2018.06.008_bb0155","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jacc.2013.09.056","article-title":"Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients","volume":"63","author":"Matsumoto","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.yjmcc.2018.06.008_bb0160","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.2013.905","article-title":"Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial","volume":"309","author":"Edelmann","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.yjmcc.2018.06.008_bb0165","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yjmcc.2018.06.008_bb0170","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jacbts.2016.03.001","article-title":"Detection and Management of Geographic Disparities in the TOPCAT trial: Lessons Learned and Derivative Recommendations","volume":"1","author":"Bristow","year":"2016","journal-title":"JACC Basic Transl. Sci."},{"key":"10.1016\/j.yjmcc.2018.06.008_bb0175","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s11897-017-0336-x","article-title":"Designing future clinical trials in heart failure with preserved ejection fraction: lessons from TOPCAT","volume":"14","author":"Patel","year":"2017","journal-title":"Curr. Heart Fail. Rep."},{"key":"10.1016\/j.yjmcc.2018.06.008_bb0180","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0895-7061(00)01245-0","article-title":"Diastolic dysfunction precedes myocardial hypertrophy in the development of hypertension","volume":"14","author":"Aeschbacher","year":"2001","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.yjmcc.2018.06.008_bb0185","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/ajh.2009.258","article-title":"Early left ventricular mechanics abnormalities in prehypertension: a two-dimensional strain echocardiography study","volume":"23","author":"Di Bello","year":"2010","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.yjmcc.2018.06.008_bb0190","doi-asserted-by":"crossref","first-page":"H1524","DOI":"10.1152\/ajpheart.00955.2010","article-title":"The onset of left ventricular diastolic dysfunction in SHR rats is not related to hypertrophy or hypertension","volume":"302","author":"Dupont","year":"2012","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.yjmcc.2018.06.008_bb0195","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1159\/000435838","article-title":"Left ventricular hypertrophy in chronic kidney disease patients: from pathophysiology to treatment","volume":"5","author":"Di Lullo","year":"2015","journal-title":"Cardiorenal Med."},{"key":"10.1016\/j.yjmcc.2018.06.008_bb0200","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1177\/1753944715591448","article-title":"Spironolactone is secure and reduces left ventricular hypertrophy in hemodialysis patients","volume":"9","author":"Feniman-De-Stefano","year":"2015","journal-title":"Ther. Adv. Cardiovasc. Dis."},{"key":"10.1016\/j.yjmcc.2018.06.008_bb0205","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/jch.12628","article-title":"Long-term effects of low-dose spironolactone on chronic Dialysis patients: a randomized placebo-controlled study","volume":"18","author":"Lin","year":"2016","journal-title":"J. Clin. Hypertens. Greenwich Conn"},{"issue":"52","key":"10.1016\/j.yjmcc.2018.06.008_bb0210","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1161\/HYPERTENSIONAHA.107.109645","article-title":"Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and prevents oxidative stress in uremic rats","volume":"1979","author":"Michea","year":"2008","journal-title":"Hypertens Dallas Tex"},{"key":"10.1016\/j.yjmcc.2018.06.008_bb0215","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1161\/01.RES.0000129254.25507.d6","article-title":"What mechanisms underlie diastolic dysfunction in heart failure?","volume":"94","author":"Kass","year":"2004","journal-title":"Circ. Res."},{"issue":"Suppl. 1","key":"10.1016\/j.yjmcc.2018.06.008_bb0220","first-page":"S62","article-title":"Cardiovascular changes in chronic renal failure--pathogenesis and therapy","volume":"58","author":"Amann","year":"2002","journal-title":"Clin. Nephrol."},{"key":"10.1016\/j.yjmcc.2018.06.008_bb0225","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1161\/CIRCULATIONAHA.108.809194","volume":"119","author":"Iraqi","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.yjmcc.2018.06.008_bb0230","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1016\/j.ajpath.2014.07.009","article-title":"Treatment with the matricellular protein CCN3 blocks and\/or reverses fibrosis development in obesity with diabetic nephropathy","volume":"184","author":"Riser","year":"2014","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.yjmcc.2018.06.008_bb0235","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/aps.2017.87","article-title":"CCN3 suppresses TGF-\u03b21-induced extracellular matrix accumulation in human mesangial cells in vitro","volume":"39","author":"Liu","year":"2018","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.yjmcc.2018.06.008_bb0240","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.bbamcr.2012.09.007","article-title":"Calcium mishandling in diastolic dysfunction: mechanisms and potential therapies","volume":"1833","author":"Asp","year":"2013","journal-title":"Biochim. Biophys. Acta BBA - Mol. Cell Res."},{"key":"10.1016\/j.yjmcc.2018.06.008_bb0245","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1161\/01.CIR.95.2.423","article-title":"Physiological effects of adenoviral gene transfer of sarcoplasmic reticulum calcium ATPase in isolated rat myocytes","volume":"95","author":"Hajjar","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.yjmcc.2018.06.008_bb0250","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/01.RES.81.2.145","article-title":"Adenoviral gene transfer of phospholamban in isolated rat cardiomyocytes. Rescue effects by concomitant gene transfer of sarcoplasmic reticulum ca(2+)-ATPase","volume":"81","author":"Hajjar","year":"1997","journal-title":"Circ. Res."},{"key":"10.1016\/j.yjmcc.2018.06.008_bb0255","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/01.ASN.0000037403.95126.03","article-title":"Effect of chronic renal failure on cardiac contractile function, calcium cycling, and gene expression of proteins important for calcium homeostasis in the rat","volume":"14","author":"Kennedy","year":"2003","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"10.1016\/j.yjmcc.2018.06.008_bb0260","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2014.00005","article-title":"The role of CaMKII regulation of phospholamban activity in heart disease","volume":"5","author":"Mattiazzi","year":"2014","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.yjmcc.2018.06.008_bb0265","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1161\/CIRCHEARTFAILURE.114.001279","article-title":"Effects of adiponectin on calcium-handling proteins in heart failure with preserved ejection fraction","volume":"7","author":"Tanaka","year":"2014","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.yjmcc.2018.06.008_bb0270","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1161\/01.RES.0000117307.57798.F5","article-title":"Frequency- and afterload-dependent cardiac modulation in vivo by troponin I with constitutively active protein kinase a phosphorylation sites","volume":"94","author":"Takimoto","year":"2004","journal-title":"Circ. Res."},{"key":"10.1016\/j.yjmcc.2018.06.008_bb0275","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.tcm.2006.05.003","article-title":"Mechanisms of diastolic dysfunction in heart failure","volume":"16","author":"Borlaug","year":"2006","journal-title":"Trends Cardiovasc. Med."},{"key":"10.1016\/j.yjmcc.2018.06.008_bb0280","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.yjmcc.2018.06.008_bb0285","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.007475","article-title":"Diastolic blood pressure and adverse outcomes in the TOPCAT (treatment of preserved cardiac function heart failure with an aldosterone antagonist) trial","volume":"7","author":"Sandesara","year":"2018","journal-title":"J. Am. Heart Assoc."}],"container-title":["Journal of Molecular and Cellular Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022282818303687?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022282818303687?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T00:52:19Z","timestamp":1535676739000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022282818303687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":57,"alternative-id":["S0022282818303687"],"URL":"https:\/\/doi.org\/10.1016\/j.yjmcc.2018.06.008","relation":{},"ISSN":["0022-2828"],"issn-type":[{"value":"0022-2828","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mineralocorticoid receptor antagonism improves diastolic dysfunction in chronic kidney disease in mice","name":"articletitle","label":"Article Title"},{"value":"Journal of Molecular and Cellular Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yjmcc.2018.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}